Policlinica Gipuzkoa S.A.

Donostia 25 trials 8 recruiting

25 Registered trials

8 Currently recruiting

Organisation

Policlinica Gipuzkoa S.A.

Location

Donostia, Spain

Identifier

ORG-100043150

Address

Paseo Miramon 174, 20009, Spain

Departments

#40541: Servicio de Neurología
Aparato Digestivo
Cardiology
Neurología
neurology
Neurology Department

Clinical trials at this site (25)

Search interface

A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending

2024-515448-22-00 Parkinson 4
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Early Alzheimer’s Disease (Mild Cognitive Impairment an 4 2024-08-12
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting

2023-504472-24-00 Early Idiopathic Parkinson’s disease (PD) 4 2024-03-19
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting

2022-500292-31-00 Early stages of idiopathic Parkinson's Disease 4 2023-05-12
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Phase 2 Study of CVN424 Ended

2024-516811-25-00 Parkinson Disease 4 2025-05-15
A Study of Remternetug in Early Alzheimer’s Disease Ended

2024-515656-20-00 Alzheimer’s Disease 5 2025-04-15
A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso… Ended

2024-511222-30-00 Multiple System Atrophy 4 2024-10-22
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Alzheimer's disease 9 2024-06-27
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 10 2021-05-11
A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended

2024-510887-22-00 Mild cognitive impairment due to Alzheimer's disease or 5 2019-09-30
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended

2022-502713-29-00 Dyskinesia due to cerebral palsy (DCP) 5 2024-03-01
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended

2024-512123-37-00 Parkinson's disease 5 2021-05-27